E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
patients with unresectable (locally advanced or metastatic) pancreatic cancer, either chemonaive or after first-line chemotherapy with a gemciatbine based regimen |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To investigate the efficacy, safety and pharmacokinetics of two dosing schedules of BI 2536 in patients with unresectable advanced pancreatic cancer, and to select the most appropriate dosing schedule for the future clinical trials programme
|
|
E.2.2 | Secondary objectives of the trial |
1.) tumour control (= “objective response” or “stable disease” after the fourth treatment courses), duration of overall response, progression free survival, overall survival, best response (confirmed and unconfirmed) evaluated according to the RECIST criteria every other course 2.) one-year survival 3.) CA19-9 response 4.) quality of life assessment, including clinical benefit response (for definition of clinical benefit response, see section 5.1.8) 5.) PK of BI 2536 6.) incidence and intensity of AEs graded according to CTCAE 7.) DLT
|
|
E.2.3 | Trial contains a sub-study | Information not present in EudraCT |
E.3 | Principal inclusion criteria |
1.) male or female patient aged 18 years or older 2.) patient with confirmed diagnosis of unresectable adenocarcinoma of the pancreas, either locally advanced or with metastases 3.) patient who is either chemonaïve (for the first line cohorts), or who presents with progressive disease under first line chemotherapy with a gemcitabine based regimen (for the second line cohort) 4.) Karnofsky performance status of ≥ 70% for the first line cohorts, and Karnofsky performance status ≥ 50% for the second line cohort 5.) patient with at least one measurable tumour lesion that can accurately be measured by magnetic resonance imaging (MRI), or computed tomography (CT) in at least one dimension (longest diameter to be recorded) 6.) life expectancy of at least three months 7.) patient must have given written informed consent consistent with the guidelines of the international conference on harmonisation for good clinical practice (ICH-GCP) as well as with local legislation
|
|
E.4 | Principal exclusion criteria |
1.) hypersensitivity to the trial drug or the excipients 2.) prior adjuvant chemotherapy for pancreatic cancer (first line patients only) 3.) persistence of toxicities of prior anti cancer therapies which are deemed to be clinically relevant 4.) known second malignancy requiring therapy 5.) brain metastases which are symptomatic or require therapy 6.) absolute neutrophil count less than 1.500/mm3 7.) platelet count less than 100.000/mm3 8.) haemoglobin less than 9 mg/dl 9.) aspartate aminotransferase (AST) or alanine aminotransferase (ALT) greater than 2.5 times the upper limit of normal, or aspartate aminotransferase (AST) or alanine aminotransferase (ALT) greater than 5 times the upper limit of normal in case of known liver metastases 10.) bilirubin greater than 3.0 mg/dl (> 52 mol/l, SI unit equivalent) under adequate drainaging measures (in case of obstructive jaundice) 11.) serum creatinine greater than 2.0 mg/dl 12.) concomitant intercurrent illnesses including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness or social situation that would limit compliance with trial requirement or which are considered relevant for the evaluation of the efficacy or safety of the trial drug 13.) radiotherapy within the past four weeks prior to treatment with the trial drug 14.) chemo-, hormone- or immunotherapy or therapy with a biologic response modifier within the past four weeks or within less than four half-life times of the previous drug prior to treatment with the trial drug (whichever is longer) 15.) treatment with any other investigational drug within the past four weeks or within less than four half-life times of the investigational drug before treatment with the trial drug (whichever is longer) 16.) men or women who are sexually active and unwilling to use a medically acceptable method of contraception during the trial 17.) pregnancy or lactation 18.) patients unable to comply with the protocol
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Primary endpoint: Best objective response evaluated according to the RECIST criteria |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The clinical trial will be considered completed as soon as the last patient has completed his / her last visit (end of trial visit). |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 3 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 5 |